Cargando…

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH

Human cytomegalovirus (CMV) is a contributing factor to tumour expansion and progression in glioblastoma patients. Patient-derived non-modified CMV-specific T cells can be isolated, ex vivo re-stimulated with CMV and expanded before IV infusion. Adoptive T cell Therapy with expanded CMV-specific T c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kampers, Linde F C, Rajabpour, Golnaz, Bitar, Michael, Schirrmacher, Volker, Stücker, Wilfried, Van Gool, Stefaan W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Immunology/Immunotherapy - IMMU
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259960/ http://dx.doi.org/10.1093/neuonc/noad073.189

Ejemplares similares

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS
por: Wilson, Zach, et al.
Publicado: (2023)

IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
por: McGuiness, James, et al.
Publicado: (2023)

IMMU-16. IDENTIFICATION OF TUMOR REJECTION ANTIGENS FOR PRECISION ADOPTIVE CELLULAR THERAPY FOR PEDIATRIC GLIOMAS
por: Trivedi, Vrunda, et al.
Publicado: (2023)

IMMU-23. RESEARCH ON MULTI-ANTIGEN T CELL INFUSION AGAINST NEURO-ONCOLOGIC DISEASE (ReMIND)
por: Cruz, Conrad Russell, et al.
Publicado: (2023)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
por: Harvey, Kyra, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
por: Ramirez, Alejandra, et al.
Publicado: (2023)

IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
por: Figg, John, et al.
Publicado: (2023)

IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT
por: Najem, Hinda, et al.
Publicado: (2023)

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
por: Hoare, Owen, et al.
Publicado: (2023)

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
por: Thompson, Eric, et al.
Publicado: (2023)

IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
por: Haydar, Dalia, et al.
Publicado: (2023)

IMMU-22. ALLOGENEIC NK CELLS SECRETING IL15 AND RESISTANT TO TGF-β Show Antitumor Activity Against Gliobastoma
por: Muniraj, Nethaji, et al.
Publicado: (2023)

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
por: Mahdi, Jasia, et al.
Publicado: (2023)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
por: Owens, Geoffrey, et al.
Publicado: (2023)

IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS
por: Lin, Frank, et al.
Publicado: (2023)

IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
por: Myers, Carrie, et al.
Publicado: (2023)

IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
por: Marquardt, Viktoria, et al.
Publicado: (2023)

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

The Application of Evidence-Based Medicine in Individualized Medicine
por: Van de Vliet, Peter, et al.
Publicado: (2023)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

IMMU-02. CH14.18 IN THE TREATMENT OF HIGH-RISK NEUROBLASTOMA: A META-ANALYSIS
por: Abdel-Khaleq, Sameerah, et al.
Publicado: (2021)

OTHER-02 BRAIN TUMORS: CLINICAL PRESENTATION AT THE NATIONAL CENTER FOR NEUROLOGICAL SCIENCES IN KHARTOUM 2019-2022
por: Nasr, Arwa, et al.
Publicado: (2023)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

MENINGIOMA-02 A RADIOLOGY- PATHOLOGICAL CORRELATION OF HYPEROSTOSIS AMONG PATIENTS WITH INTRACRANIAL MENINGIOMAS AT THE KENYATTA NATIONAL HOSPITAL.
por: Marjorie, Adagi, et al.
Publicado: (2023)

GLIOMA-02 HISTOPATHOLOGIC AND MOLECULAR PROFILE OF GLIOMAS: A 9-YEAR RETROSPECTIVE STUDY OF CASES DIAGNOSED IN LAGOS NIGERIA
por: Odukoya, Lateef, et al.
Publicado: (2023)

IMMU-09. NIVOLUMAB THERAPY FOR A PEDIATRIC-ONSET PRIMARY INTRACRANIAL MELANOMA
por: Oba, Utako, et al.
Publicado: (2020)

IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model
por: Tsahouridis, Rania, et al.
Publicado: (2022)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

GLIOMA-15 RETROSPECTIVE REVIEW OF GLIOBLASTOMA MULTIFORME CASES MANAGED AT A TERTIARY LEVEL HOSPITAL IN KENYA
por: Sharma, Karishma, et al.
Publicado: (2023)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

NEIM-14 PET/MRI DETECTS A RAPID DECREASE IN CEREBRAL BLOOD FLOW IN GLIOBLASTOMA FOLLOWING BEVACIZUMAB INFUSION
por: Thaw-Poon, Serena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rk1vrmqfevuh419rbn0jd9m2id